CP 154526

Key Product Details

Product Description

CP 154526 is a selective, non-peptide CRF₁ receptor antagonist (K_i values are 2.7 and > 10000 nM for CRF₁ and CRF₂ receptors respectively). Blocks CRF-induced adenylate cyclase activation (K_i = 3.7 nM) and attenuates activation of the HPA axis by CRF. Displays anxiolytic-like activity in the rat elevated plus-maze test; brain penetrant.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for CP 154526

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CP 154526

The following data is based on the product molecular weight 400.99.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.99 mL	24.94 mL	49.88 mL
2.5 mM	1.00 mL	4.99 mL	9.98 mL
5 mM	0.50 mL	2.49 mL	4.99 mL
25 mM	0.10 mL	0.50 mL	1.00 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 17 publications citing the usage of this product.

• Hodgson Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol.Biochem.Behav. 2007 PMID: 17291571
• Schulz CP-154,526: a potent and selective nonpeptide antagonist of cortico. releasing factor receptors. Proc.Natl.Acad.Sci.USA 1996 PMID: 8816826
• Lundkist A non peptidic cortico. releasing factor receptor antagonist attenuates fever and exhibits anxiolytic activity. Eur.J.Pharmacol. 1996 PMID: 8874139

Product Documents for CP 154526